SYNMOSA Biopharma announced that its consolidated revenue for May reached NT$532 million, marking a 5.9% increase from the previous month and a 10.2% increase year-on-year—another strong performance in its operations. Cumulative revenue for the first five months of the year totaled NT$2.487 billion, reflecting an 11% year-on-year growth and highlighting the company's steady overall momentum.
Among the various business divisions, the oncology segment, which has actively introduced and distributed multiple new products, achieved the most significant growth. From January to May, cumulative revenue from this segment increased by more than 70% year-on-year, underscoring SYNMOSA’s strong potential in the cancer treatment market. The company remains committed to introducing innovative therapies and supporting continuous advancement in clinical care, and plans to collaborate with original manufacturers to drive more international academic exchange and cooperation in oncology.
The impact of the drug licenses obtained last year is also starting to manifest, bringing notable revenue contributions across various indications. Products in the cardiovascular and neuropsychiatric areas have both shown strong double-digit growth. In the gastrointestinal segment, long-standing bestsellers such as Colacein and Stanin continued to perform well, supported by active participation in academic conferences and enhanced brand visibility, leading to robust market results.
Internationally, the Hong Kong market saw nearly double-digit revenue growth year-to-date, while Macau achieved a remarkable 40% increase. The teams in both regions have actively participated in local medical conferences, boosting SYNMOSA’s visibility in the healthcare community. With successful entry into public and private hospital channels, sales have grown rapidly. Leveraging this solid foundation, the company continues to introduce new products and refine its portfolio, fueling the next phase of growth.
SYNMOSA’s revenue growth is the result of multifaceted efforts, clearly demonstrating the competitive advantage gained through long-term vertical integration and strategic partnerships. Looking ahead, the company will continue to deepen its presence in niche drug markets, expand its diversified product portfolio, and enhance the quality of its offerings and services. By integrating internal resources and maintaining close collaboration with external partners, SYNMOSA is building multiple engines of growth, steadily strengthening its leadership in the pharmaceutical industry, and delivering high-value innovative solutions to the market.
Resource: 健喬5月合併營收達5.32億元 月、年雙增
